《新股消息》百威亞太(01876.HK)明起招股入場費4,747.36元
百威亞太(01876.HK)明起至7月11日招股,每股招股價介乎40-47元,每手100股計,入場費4,747.36元。
是次共發行16.27億股,其中5%在港作公開發售,摩根大通和摩根士丹利為聯席保薦人。股份會於7月19日上市。
以中位數計,集資淨額為692.5億元,會即時用於償還應付百威集團附屬公司的貸款以完成重組,包括全數償還韓國債務應收貸款項下,對Mexbrew Investment SARL的債務;及償還股東貸款項下對AB InBev Investment的部份債務。
若超額配股權得以行駛,將償還對APAC HoldCo2 的債務;若未能行使,則會向其發行相同數目股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.